HUCMSC-derived therapy decreased patient blood plasma markers of vascular (endothelial) fibrosis (NEDD9 (ref. 21)), vascular injury (ICAM-1) and inflammation (SAA; IFN-γ) (Fig. 2c–f). This evidence concerns the gene IFNG and fibrosis.